The new tissue model kits were developed to provide customers with tissue-specific bioinks and antibodies. The kits include antibodies from Atlas Antibodies, a collaborator with extensive experience in antibody development and production.
CELLINK, the world’s first bioink company and a global leader in bioprinter systems and bioinks, continues innovating new ways to strengthen its position in the field.
Today, CELLINK is announcing the launch of two new tissue model kits — CELLINK SKIN Kit and CELLINK LIVER Kit. These kits give users valuable information about the phenotype of their tissue models. This insight enables better understanding of tissue health and helps researchers develop reliable tissue models for drug screening and cosmetic testing. With this launch, we continue to grow our product portfolio and offer an increasingly extensive range of tools to enhance research worldwide.
These kits are commercially available now through CELLINK and partners. This launch is the first of a multiphase initiative to better serve the needs of our collaborators.
For more information, please contact:
Erik Gatenholm, CEO Gusten Danielsson, CFO
Phone: EU +46 73 267 00 00 Phone: +46 70 991 86 04
US +1 (650) 515 5566 US +1 (857) 332 2138
CELLINK is the leading 3D bioprinter provider and the first bioink company in the world. We focus on developing and commercializing bioprinting technologies to allow researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 and active in more than 50 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North under CLNK. Erik Penser Bank AB is the company’s certified adviser, available by phone at +46 846 383 00 and by email at: [email protected].